What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Namiki Izumi focuses on Internal medicine, Hepatocellular carcinoma, Gastroenterology, Virology and Hepatitis C virus.
His Internal medicine research is multidisciplinary, incorporating perspectives in Ribavirin, Surgery and Immunology.
The study incorporates disciplines such as Carcinoma and Hazard ratio in addition to Hepatocellular carcinoma.
His studies in Gastroenterology integrate themes in fields like Stage, Adverse effect and Cohort study.
His work in Virology tackles topics such as Genotype which are related to areas like Fulminant hepatitis and Acute hepatitis B.
Namiki Izumi works mostly in the field of Interferon, limiting it down to concerns involving NS5A and, occasionally, Peptide sequence.
His most cited work include:
- Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. (1953 citations)
- Mutations in the Nonstructural Protein 5a Gene and Response to Interferon in Patients with Chronic Hepatitis C Virus 1b Infection (953 citations)
- Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. (602 citations)
What are the main themes of his work throughout his whole career to date?
Namiki Izumi mainly investigates Internal medicine, Gastroenterology, Hepatocellular carcinoma, Virology and Hepatitis C virus.
His work carried out in the field of Internal medicine brings together such families of science as Ribavirin and Oncology.
His Ribavirin research includes elements of Interferon and Combination therapy.
His work focuses on many connections between Gastroenterology and other disciplines, such as Adverse effect, that overlap with his field of interest in Placebo.
His Hepatocellular carcinoma research includes themes of Carcinoma, Surgery and Hazard ratio.
His Hepatitis C virus study is concerned with the larger field of Immunology.
He most often published in these fields:
- Internal medicine (60.44%)
- Gastroenterology (40.96%)
- Hepatocellular carcinoma (40.36%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (60.44%)
- Hepatocellular carcinoma (40.36%)
- Gastroenterology (40.96%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Hepatocellular carcinoma, Gastroenterology, In patient and Oncology are his primary areas of study.
His is doing research in Hazard ratio, Adverse effect, Confidence interval, Hepatology and Clinical trial, both of which are found in Internal medicine.
Namiki Izumi works mostly in the field of Hepatology, limiting it down to topics relating to Hepatitis C virus and, in certain cases, Hemodialysis, as a part of the same area of interest.
His Hepatocellular carcinoma study incorporates themes from Liver function and Cohort.
Namiki Izumi interconnects Fibrosis and Incidence in the investigation of issues within Gastroenterology.
Namiki Izumi has included themes like Hepatitis B and Hepatitis C in his Cirrhosis study.
Between 2018 and 2021, his most popular works were:
- Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. (91 citations)
- Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. (73 citations)
- Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study (44 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His primary scientific interests are in Internal medicine, Hepatocellular carcinoma, Gastroenterology, Adverse effect and Lenvatinib.
His work in Internal medicine is not limited to one particular discipline; it also encompasses Hepatectomy.
His Hepatocellular carcinoma research is multidisciplinary, incorporating elements of Carcinoma, Oncology, Cohort and Hazard ratio.
Namiki Izumi focuses mostly in the field of Gastroenterology, narrowing it down to topics relating to Receiver operating characteristic and, in certain cases, Mac 2 binding protein and Subgroup analysis.
His Adverse effect study integrates concerns from other disciplines, such as Hepatitis C virus, Platelet, Platelet transfusion, Chronic liver disease and Placebo.
His research integrates issues of Ribavirin, DIRECT ACTING ANTIVIRALS, Sustained Virologic Responses, Sofosbuvir and Anemia in his study of Hepatitis C.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
